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An analytical evaluation of the thyroid stimulating hor-
mone (TSH-3) assay on the Bayer ADVIA® Centaur™
immunoassay system was performed. General analyt-
ical requirements (linearity, resistance to typical inter-
ferences, absence of a carry-over effect) were fulfilled
and reproducibility was satisfactory. Inter-assay coeffi-
cient of variation (CV) of a human serum pool with a
concentration of 0.014 mU/l was 22.3%; at concentra-
tions between 0.26 and 83 mU/l CV was below 6%.
Method comparison study demonstrated close agree-
ment of TSH results compared to those obtained with
the Roche Elecsys® 2010 TSH assay (ADVIA Centaur =
1.08 x Elecsys – 0.18 mU/l; r=0.987; n=324). Handling
and practicability of the ADVIA Centaur system proved
to be convenient with a very high sample throughput.
We conclude that the ADVIA Centaur TSH-3 assay
meets requirements for clinical use.
Key words: TSH (thyrotropin); Immunoassay; Automa-
tion; ADVIA® Centaur™.
Abbreviations: CV, coefficient of variation; TSH, thyroid
stimulating hormone (thyrotropin).
Introduction
Thyrotropin (TSH) is now generally accepted as the
first line parameter in the screening for thyroid dis-
eases (1). Since the prevalence of thyroid diseases is
high in the general population, especially in iodine de-
ficient regions (2), and symptoms are rather unspecific
in many cases, screening for thyroid disorders is indi-
cated in a large proportion of patients requiring med-
ical attention. Therefore TSH assays represent one of
the highest volume immunoassays in many clinical
laboratories. Consequently, reliable automation is of
particular importance for TSH determinations. 
The third generation TSH assay implemented on the
Bayer ACS:180® immunoassay analyzer has been
widely used for several years now and evaluation data
has been published previously (3–6). This TSH assay is
now available on the new ADVIA® Centaur™ immuno-
analyzer (formerly designated as the ACS:Centaur® im-
munoanalyzer) with the added feature of an exception-
ally high sample throughput. The aim of our study was
to investigate whether the rapid throughput of the
Bayer ADVIA® Centaur™ TSH-3 assay maintained ac-
ceptable assay performance.
Materials and Methods
Instruments
The ADVIA Centaur analyzer system (Bayer Diagnostics, Tar-
rytown, NY, formerly Chiron Diagnostics, East Walpole, MA,
USA) is a stand alone analyzer providing the features that are
characteristic for modern automated immunoassay systems:
random-access and multichannel working mode, calibration
stability, positive sample identification by a bar-code reader,
and bi-directional interface to a laboratory software system.
Sample tubes are released within three minutes after pipet-
ting for further processing. All reagents and supply materials
(water, cuvettes, pipette tips) may be refilled and waste may
be emptied during a run. Reagents are mixed manually before
loading and can then remain on-board the assay system for 28
days. Both assay cuvettes and pipette-tips are disposable sin-
gle use materials. The system is equipped with a clot-detec-
tion device. Daily maintenance consists of an automated
washing procedure that takes about 40 minutes and the rou-
tine start-up takes about 10 minutes. The maximum through-
put is 240 samples per hour. The analyzer requires an area of
approximately 2.5 square meters for installation.
Assay characteristics
The ADVIA Centaur TSH-3 assay (Bayer Diagnostics) is a sand-
wich immunoassay using paramagnetic microparticles as
solid phase and direct chemiluminescence of acridinium ester
for detection of specific signal. Two hundred microliters (ml)
of sample are dispensed in a cuvette, and 100 µl of a buffered
solution of a monoclonal anti-TSH antibody labeled with an
acridinium ester are added and incubated at 37°C for 2.5 min-
utes. A homogenized suspension of the paramagnetic mi-
croparticles (225 µl) coated with a polyclonal sheep-anti-TSH
antibody is then added; incubation for 5 minutes allows for-
mation of the sandwich. The microparticles are separated
with magnets from the solution and washed. Acid and base
reagent additions trigger the chemiluminescent reaction, that
is detected by a photomultiplier. The intensity of the light sig-
nal measured over 5 seconds is directly related to the TSH
concentration in the sample. A predefined master calibration
curve of the respective reagent lot is read from the reagent
cartridges by a barcode scanner. This master curve is adjusted
by the customer using two calibrators when a new reagent lot
is first introduced and after a recommended interval of 28
days. The assay is standardized according to the international
standard preparation 2nd IRP 80/558 (WHO). The measuring
range of the assay is from 0.004 mU/l (analytical sensitivity) to
150 mU/l. Results are reported approximately 15 minutes after
pipetting the sample. The reference range recommended by
Bayer Germany for the ADVIA Centaur TSH-3 assay is 0.35–4.5
mU/l.
Assay studies
Imprecision study
Human serum pools at five concentration levels were pre-
pared from serum samples, aliquoted after overnight equili-
bration, and stored at –20°C. Lyophilized control materials at
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three concentration levels (Ligand Plus 1,2,3 Quality Control
material; Bayer Diagnostics) were reconstituted with deion-
ized water and used within three days thereafter. Intra-assay
imprecision studies in 21 replicates were performed using the
human serum pools. To study inter-assay imprecision the
aliquoted human serum pools and the control materials were
analyzed in 21 runs over a 35-day period in singlicates; two
different lots of reagents and calibrators were used. Recali-
bration was performed every two weeks.
Carry-over study
A sample of a patient with hyperthyroidism was measured in
five replicates directly after five replicates of a sample with a
high TSH concentration.
Linearity study
A high-TSH human serum pool (91 mU/l) was diluted in nine
steps with a low-TSH human serum pool (0.008 mU/l) (9+1,
8+2, … 2+8, 1+9 volumes of the high and the low pool, respec-
tively). TSH concentrations of the diluted samples were deter-
mined after two hours of equilibration; Pearson’s correlation
coefficient was calculated for the results obtained from the
eleven samples. Linearity in the lower measuring range was
tested by diluting a serum pool with a concentration of 1.9
mU/l with the low-TSH pool using the same dilution se-
quence.
Interference studies
Possible interference with the assay from sera of patients with
uremia, cholestasis, lipemia or heterophilic antibodies was
assessed by dilution experiments. The same nine-step dilu-
tion sequence as used for the linearity investigations was ap-
plied using four high-interferent pools (lipemia, triglycerides
11.5 mmol/l; uremia, creatinine 778 µmol/l; icterus, bilirubin
231 µmol/l; heterophilic antibodies, 65 IU/ml (N Latex RF,
nephelometric assay, Dade Behring, Marburg, Germany) and
one normal pool, respectively, the latter with a TSH concen-
tration of 0.14 mU/l. Pearson’s coefficient of correlation was
calculated for the four respective studies; if linearity of TSH
results was found in the dilution series (r>0.98) absence of rel-
evant interference by the respective factors in the given con-
centrations was assumed. To study the influence of hemoly-
sis, 2 ml of a human serum pool were spiked with 10 µl of a
hemolysate obtained by freezing a whole blood sample, re-
sulting in a free hemoglobin concentration of 2.9 µmol/l; TSH
was measured in triplicate before and after spiking, respec-
tively.
Method comparison
Serum samples for TSH determination obtained over a one
month period by the Clinic of Nuclear Medicine of our institu-
tion were used for a method comparison study. Included in
this study were 32 patients with overt hyperthyroidism before
and during radioiodine therapy, 28 patients during thyroxine
withdrawal before undergoing radioiodine therapy for differ-
entiated thyroid carcinoma, and 61 patients under long term
thyroxine substitution after treatment for thyroid carcinoma.
Additionally 265 routine consecutive samples sent for TSH de-
termination were included in the method comparison (168
outpatients, 97 hospitalized patients including 58 intensive
care patients); a total of 389 samples from 380 patients was
studied.
The results of the ADVIA Centaur TSH-3 assay were com-
pared with those obtained with our current routine method,
the Roche Elecsys® 2010 TSH assay (Roche Diagnostic Sys-
tems, Mannheim, Germany); this immunoassay system uses
microparticles as solid phase as well, but electrochemilumi-
nescence as principle of signal generation. The Elecsys TSH
assay, a sandwich assay with two monoclonal antibodies
(standardized according to the IRP WHO standard preparation
80/558; sample volume 50 µl) has been evaluated previously
(7). Single measurements were performed within four hours
on both assay systems. Samples with a TSH concentration
above 100 mU/l found with the Elecsys assay were not in-
cluded in the study. The results of the two assays were ana-
lyzed by linear regression. Additionally the mean difference
between the two assays was calculated as described by Bland
and Altman (8).
All handling instructions of the manufacturer were followed
in all regards and quality control was performed in each run
according to the guidelines of the German Medical Associa-
tion by use of three commercial control materials (see above).
Results
In the imprecision study, an inter-assay coefficient of
variation (CV) of 22.3% was obtained in a human serum
pool with a TSH concentration found at 0.014 mU/l. For
the other pools and the control materials CVs below 6%
were found (Table 1).
No carry-over effect was detected. After five determi-
nations of TSH in a sample with a concentration of 83
mU/l, five consecutive results of low-TSH sample were
as follows: 0.025, 0.029, 0.029, 0.027, and 0.026 mU/l.
Tab. 1 Imprecision study of the ADVIA Centaur TSH-3 assay.
Sample Mean TSH Intra-assay Inter-assay 
concentration (mU/l) imprecision (CV%) imprecision (CV%)
n=21 n=21
Pool 1 0.014 16.7% 22.3%
Pool 2 0.26 3.9% 5.5%
Control Ligand 1 0.51 5.5%
Pool 3 0.98 2.4% 5.1%
Control Ligand 2 4.38 5.8%
Pool 5 6.80 2.9% 3.1%
Control Ligand 3 16.4 5.5%
Pool 6 83.2 2.8% 4.4%
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In the dilution experiments, linearity of the TSH re-
sults was demonstrated in the studied range up to 91
mU/l through a correlation coefficient of 0.998. The as-
say proved linear in the low measuring area (< 1.9
mU/l) as well (r = 0.998). 
No analytical interference from uremia, cholestasis,
and heterophilic antibodies was found in our experi-
ments, with correlation coefficients >0.98 for each of
the dilution experiments. Marked hemolysis led to
slightly lower results; in a sample with a TSH concen-
tration of 2.37 mU/l, spiking with hemolysate leading to
free hemoglobin concentrations of 2.0 and 5.0 g/l, re-
spectively, caused a decrease of TSH results by –3.6%
and –8.8%.
In the method comparison study, 324 results within
the range of 0.02 mU/l (wich was assumed as func-
tional sensitivity of the assays) and 100 mU/l were
found (see Figure 1). 
The mean concentration of these samples was 4.9
mU/l (SD 11.6, median 1.2) with the ADVIA Centaur as-
say, and 4.7 mU/l (SD 12.7, median 1.2) with the Elecsys
assay. The mean percentage difference between the
two assays (ADVIA Centaur results subtracted from the
respective Elecsys results, according to Bland and Alt-
man (7)) was +3.8% (SD 14.2%). Linear regression
analysis revealed the following equations for the differ-
ent concentration ranges:
0.02–100 mU/l: ADVIA Centaur = 1.08 x Elecsys –
0.18 mU/l (n=324; r=0.987)
0.02–1.0 mU/l: ADVIA Centaur = 0.93 x Elecsys +
0.004 mU/l (n=127; r=0.982)
Among the population studied, 65 patients had very
low TSH concentrations. In 61 sample both assays
measured concentrations below 0.02 mU/l; in four
samples one of the assays found a concentration be-
low 0.02 mU/l, the other showed slightly higher results
(TSH in mU/l: sample 1, Elecsys 0.023, Centaur 0.019;
sample 2, Elecsys 0.012, Centaur 0.023; sample 3, Elec-
sys 0.016, Centaur 0.027; sample 4, Elecsys 0.018, Cen-
taur 0.031). The most marked relative difference be-
tween Centaur and Elecsys TSH results (0.08 mU/l, and
0.02 mU/l, respectively) was found in a sample from a
surgical intensive care patient; both serum free thyrox-
ine and triiodothyronine were low, representing the
characteristic constellation seen in severe non-thy-
roidal illness.
The test throughput of 240 determinations per hour
specified for the ADVIA Centaur could be verified in our
experiments.
Discussion
The ADVIA Centaur TSH-3 assay demonstrated satis-
factory precision in our experiments and fulfilled the
criteria of a third generation TSH assay (9, 10). Long-
term stability of the assay results will depend on pro-
duction quality of all following lots and will be as-
sessed prospectively. Similiar imprecision data have
been reported for automated chemiluminescence as-
says (4, 5, 11).
Further general analytical requirements of the AD-
VIA Centaur TSH-3 assay could be verified: dilution lin-
earity was found to be satisfactory over the whole
range, as well as in the low measuring range, and no
carry-over effect was detected. The assay was unaf-
fected by typical assay interferences, except for
marked hemolysis.
The ADVIA Centaur TSH results were in very close
agreement to those obtained with our current routine
method in a large number of clinical samples from pa-
tients with various thyroid disorders over a wide con-
centration range; even in the very low range the diag-
nostic agreement of both assays was excellent.
The high sample volume (200 µl) necessary for a TSH
determination may limit the use of the ADVIA Centaur
TSH-3 assay in pediatric medicine.
The high sample throughput of the ADVIA Centaur
analyzer, 240 determinations per hour as specified by
the manufacturer, was indeed realized during our eval-
uation. Reagent and disposal handling was easy and
convenient. The same applies for the system software.
Our experiences with regard to practicality were satis-
factory.
In summary, we conclude from our evaluation data
that the ADVIA Centaur TSH-3 assay meets the analyti-
cal quality requirements for its routine clinical use as
well as for a high sample throughput.
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